P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
K. Hatanaka
◽
S. Yuki
◽
H. Nakatsumi
◽
A. Hosokawa
◽
M. Nakamura
◽
...
T. Ando
◽
S. Yuki
◽
H. Nakatsumi
◽
T. Muranaka
◽
A. Hosokawa
◽
...
2016 ◽
Vol 27
(suppl_9)
◽
T. Ando
◽
S. Yuki
◽
H. Nakatsumi
◽
T. Muranaka
◽
A. Hosokawa
◽
...
2019 ◽
Vol 110
(3)
◽
pp. 1032-1043
◽
Tadamichi Denda
◽
Daisuke Sakai
◽
Tetsuya Hamaguchi
◽
Naotoshi Sugimoto
◽
Takashi Ura
◽
...
M. Dazai
◽
S. Yuki
◽
K. Sawada
◽
T. Muranaka
◽
Y. Kawamoto
◽
...
M. Nakamura
◽
Y. Komatsu
◽
T. Muranaka
◽
M. Yagisawa
◽
Y. Kawamoto
◽
...
Julien Taïeb
◽
Thierry André
◽
Farid El Hajbi
◽
Emilie Barbier
◽
Clémence Toullec
◽
...
2014 ◽
Vol 25
◽
pp. ii107
E. Elez
◽
I. Kocáková
◽
T. Höhler
◽
U. Martens
◽
C. Bokemeyer
◽
...
2014 ◽
Vol 25
◽
pp. iv541
H. Fukushima
◽
S. Yuki
◽
H. Nakatsumi
◽
H. Hayashi
◽
K. Harada
◽
...
2013 ◽
Vol 45
◽
pp. S253-S254
G. Fiorentini
◽
C. Aliberti
◽
P. Coschiera
◽
M. Tilli
◽
L. Mulazzani
◽
...
Close
Export Citation Format
Close
Share Document
Close